Varenicline-induced acute dystonic reaction: A case report

General Hospital Psychiatry

Volumn 36, Issue 3, 2014, Pages 361.e1-361.e2

  Uca, Ali Ulvi ^a   Kozak, Hasan Hüseyin ^a   Uguz, Faruk ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Dytonic reaction; Varenicline

Indexed keywords

BIPERIDEN; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ACUTE DISEASE; ADULT; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DRUG WITHDRAWAL; DYSTONIA; EMERGENCY WARD; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INVOLUNTARY MOVEMENT; MALE; SINGLE MAN; SMOKING CESSATION; TOBACCO DEPENDENCE; CHEMICALLY INDUCED; PROCEDURES;

ADULT; BENZAZEPINES; DYSTONIA; HUMANS; MALE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; VARENICLINE;

EID: 84898630421     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2014.01.007     Document Type: Article

References (16)

1. Argüder E., Karalezli A., Hezer H., Kiliç H., Er M., et al. Sigara birakma başarisini etkileyen faktörler. Turk Toraks Derg 2013, 14:81-87. (in Turkish).
2. American Psychiatric Association Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996, 153:1-31.
3. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
4. Nides M., Glover E.D., Reus V.I., Christen A.G., Make B.J., Billing C.B., et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008, 32:664-675.
5. Kasliwal R., Wilton L.V., Shakir S.A. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009, 32:409-418.
6. US Food and Drug Administration FDA issues public health advisory on Chantix http://www.fda.gov/bbs/topics/NEWS/2008/NEW01788.html.
7. Ahmed A.I., Ali A.N., Kramers C., Härmark L.V., Burger D.M., Verhoeven W.M. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol. 2013, 33:55-62.
8. Prochaska J.J., Hilton J.F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012, 4:344.
9. Haber S.L., Boomershine V., Raney E. Safety of varenicline in patients with cardiovascular disease. J Pharm Pract. 2014, 27:65-70.
10. Jiménez-Jiménez F.J., García-Ruiz P.J., Molina J.A. Drug-induced movement disorders. Drug Saf 1997, 16:180-204.
11. Neychev V.K., Gross R.E., Lehéricy S., Hess E.J., Jinnah H.A. The functional neuroanatomy of dystonia. Neurobiol Dis 2011, 42:185-201.
12. Tanabe Lauren M., Kim Connie E., Alagem Noga, Dauer William T. Primary dystonia: molecules and mechanisms. Nat Rev Neurol 2009, 5:598-609.
13. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006, 60:571-576.
14. Fatemi S.H., Yousefi M.K., Kneeland R.E., Liesch S.B., Folsom T.D., Thuras P.D. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. Schizophr Res 2013, 146:376-378.
15. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012, 4.
16. Klinkenberg I., Blokland A., Riedel W., Sambeth A. Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden. Int J Neuropsychopharmacol 2012, 15:1375-1385.